84 related articles for article (PubMed ID: 24430933)
1. Including network knowledge into Cox regression models for biomarker signature discovery.
Fröhlich H
Biom J; 2014 Mar; 56(2):287-306. PubMed ID: 24430933
[TBL] [Abstract][Full Text] [Related]
2. Model selection for prognostic time-to-event gene signature discovery with applications in early breast cancer data.
Ahdesmäki M; Lancashire L; Proutski V; Wilson C; Davison TS; Harkin DP; Kennedy RD
Stat Appl Genet Mol Biol; 2013 Oct; 12(5):619-35. PubMed ID: 24077567
[TBL] [Abstract][Full Text] [Related]
3. Biomarker gene signature discovery integrating network knowledge.
Cun Y; Fröhlich H
Biology (Basel); 2012 Feb; 1(1):5-17. PubMed ID: 24832044
[TBL] [Abstract][Full Text] [Related]
4. Mixture classification model based on clinical markers for breast cancer prognosis.
Zeng T; Liu J
Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
[TBL] [Abstract][Full Text] [Related]
5. Network and data integration for biomarker signature discovery via network smoothed T-statistics.
Cun Y; Fröhlich H
PLoS One; 2013; 8(9):e73074. PubMed ID: 24019896
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles in esophageal adenocarcinoma predict survival after resection.
Pennathur A; Xi L; Litle VR; Gooding WE; Krasinskas A; Landreneau RJ; Godfrey TE; Luketich JD
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):505-12; discussion 512-3. PubMed ID: 23321130
[TBL] [Abstract][Full Text] [Related]
7. Network based consensus gene signatures for biomarker discovery in breast cancer.
Fröhlich H
PLoS One; 2011; 6(10):e25364. PubMed ID: 22046239
[TBL] [Abstract][Full Text] [Related]
8. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data.
Gui J; Li H
Bioinformatics; 2005 Jul; 21(13):3001-8. PubMed ID: 15814556
[TBL] [Abstract][Full Text] [Related]
9. Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations.
Kreike B; Hart G; Bartelink H; van de Vijver MJ
Breast Cancer Res Treat; 2010 Aug; 122(3):711-20. PubMed ID: 19859804
[TBL] [Abstract][Full Text] [Related]
10. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
Oberthuer A; Berthold F; Warnat P; Hero B; Kahlert Y; Spitz R; Ernestus K; König R; Haas S; Eils R; Schwab M; Brors B; Westermann F; Fischer M
J Clin Oncol; 2006 Nov; 24(31):5070-8. PubMed ID: 17075126
[TBL] [Abstract][Full Text] [Related]
11. Prognostic applications of gene expression signatures in breast cancer.
Normanno N; De Luca A; Carotenuto P; Lamura L; Oliva I; D'Alessio A
Oncology; 2009; 77 Suppl 1():2-8. PubMed ID: 20130425
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
Chang W; Gao X; Han Y; Du Y; Liu Q; Wang L; Tan X; Zhang Q; Liu Y; Zhu Y; Yu Y; Fan X; Zhang H; Zhou W; Wang J; Fu C; Cao G
Gut; 2014 Sep; 63(9):1457-67. PubMed ID: 24173294
[TBL] [Abstract][Full Text] [Related]
13. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
14. Network-Assisted Disease Classification and Biomarker Discovery.
Strunz S; Wolkenhauer O; de la Fuente A
Methods Mol Biol; 2016; 1386():353-74. PubMed ID: 26677191
[TBL] [Abstract][Full Text] [Related]
15. Regularized logistic regression with network-based pairwise interaction for biomarker identification in breast cancer.
Wu MY; Zhang XF; Dai DQ; Ou-Yang L; Zhu Y; Yan H
BMC Bioinformatics; 2016 Feb; 17():108. PubMed ID: 26921029
[TBL] [Abstract][Full Text] [Related]
16. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
Coutant C; Rouzier R; Qi Y; Lehmann-Che J; Bianchini G; Iwamoto T; Hortobagyi GN; Symmans WF; Uzan S; Andre F; de Thé H; Pusztai L
Clin Cancer Res; 2011 Apr; 17(8):2591-601. PubMed ID: 21248301
[TBL] [Abstract][Full Text] [Related]
17. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
[TBL] [Abstract][Full Text] [Related]
18. Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine.
Miller LD; Liu ET
Breast Cancer Res; 2007; 9(2):206. PubMed ID: 17397520
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial biomarker expression in breast cancer.
Rakha EA; Reis-Filho JS; Ellis IO
Breast Cancer Res Treat; 2010 Apr; 120(2):293-308. PubMed ID: 20107892
[TBL] [Abstract][Full Text] [Related]
20. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P
J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
